Company profile QNCX

Quince Therapeutics Inc
cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards hu...man clinical testing. Show More
Quarter analysis & expected interestLast update: February 07 2024 23:46:41.

After 38 days of this quarter the interest is at 26.0. Based on that we can calculate that during remaining 53 days it will total up to 62.0.
Quince Therapeutics expected interest is significantly lower compared to same quarter last year (-69.8%) but higher than previous quarter (+63.2%).

YearQ1Q2Q3Q4
201954
103
90.7% QoQ
34
-67.0% QoQ
132
288.2% QoQ
2020 0
-100.0% YoY -100.0% QoQ
156
51.5% YoY inf% QoQ
54
58.8% YoY -65.4% QoQ
145
9.8% YoY 168.5% QoQ
2021 0
9.8% YoY -100.0% QoQ
24
-84.6% YoY inf% QoQ
66
22.2% YoY 175.0% QoQ
30
-79.3% YoY -54.5% QoQ
2022 88
inf% YoY 193.3% QoQ
69
187.5% YoY -21.6% QoQ
141
113.6% YoY 104.3% QoQ
85
183.3% YoY -39.7% QoQ
2023 205
133.0% YoY 141.2% QoQ
307
344.9% YoY 49.8% QoQ
213
51.1% YoY -30.6% QoQ
38
-55.3% YoY -82.2% QoQ
2024 26
-87.3% YoY -31.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Quince Therapeutics search interestLast update: February 07 2024 23:46:41.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:46:42.

The average 5 years interest of Quince Therapeutics was 7.58 per week.
The last year interest of Quince Therapeutics compared to the last 5 years has changed by 76.39%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 115.3%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics NOV004 to provide analysis

Correlation between past revenue and Quince Therapeutics NOV004 search interest

There is not enough data for Quince Therapeutics NOV004 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics NOV004 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics precision therapeutics to provide analysis

Correlation between past revenue and Quince Therapeutics precision therapeutics search interest

There is not enough data for Quince Therapeutics precision therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics precision therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics bone anabolic peptide to provide analysis

Correlation between past revenue and Quince Therapeutics bone anabolic peptide search interest

There is not enough data for Quince Therapeutics bone anabolic peptide to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics bone anabolic peptide to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics rare diseases to provide analysis

Correlation between past revenue and Quince Therapeutics rare diseases search interest

There is not enough data for Quince Therapeutics rare diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics rare diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics NOV004 clinical trials to provide analysis

Correlation between past revenue and Quince Therapeutics NOV004 clinical trials search interest

There is not enough data for Quince Therapeutics NOV004 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics NOV004 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics South San Francisco to provide analysis

Correlation between past revenue and Quince Therapeutics South San Francisco search interest

There is not enough data for Quince Therapeutics South San Francisco to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics South San Francisco to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics biopharmaceutical company to provide analysis

Correlation between past revenue and Quince Therapeutics biopharmaceutical company search interest

There is not enough data for Quince Therapeutics biopharmaceutical company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics biopharmaceutical company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Quince Therapeutics Cortexyme to provide analysis

Correlation between past revenue and Quince Therapeutics Cortexyme search interest

There is not enough data for Quince Therapeutics Cortexyme to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Quince Therapeutics Cortexyme to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for QNCX
Earnings date: 2024-03-11 After close
Company name: Quince Therapeutics Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-09T11:25:20.043824222Z

Analyst Upgrades
Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72

2026-09-24T11:56:15.389846806Z

Analyst Upgrades
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

2026-09-24T11:41:34.688075342Z

Analyst Upgrades
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

2026-09-22T12:50:45.324254361Z

Analyst Upgrades
Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

2026-09-17T05:00:00-07:00

GlobeNewswire
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

2026-09-03T05:00:00-07:00

GlobeNewswire
Quince Therapeutics to Participate in September 2026 Investor Conferences

2026-08-18T10:59:51.461343491Z

Analyst Upgrades
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

2026-08-14T05:00:00-07:00

GlobeNewswire
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

2026-07-29T16:23:47.291735423Z

Analyst Upgrades
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

2026-06-30T05:00:00-07:00

GlobeNewswire
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

2026-06-24T18:44:38.951425996Z

Analyst Upgrades
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

2026-06-23T16:10:14.375320123Z

Analyst Upgrades
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4

2026-05-18T14:21:49Z

GlobeNewswire
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

2026-05-18T13:26:51Z

GlobeNewswire
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

2026-05-18T13:26:19Z

GlobeNewswire
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD